Zobrazeno 1 - 10
of 13
pro vyhledávání: '"C K, Schneider"'
Autor:
C K Schneider, M Weise
Publikováno v:
Zeitschrift für Rheumatologie. 74:695-700
Background Biosimilars are currently a hot topic and there are many unsolved questions, misunderstandings and sometimes considerable uncertainty, especially among clinicians and patients. Regulatory agencies, such as the European Medicines Agency (EM
Autor:
C. K. Schneider, Harald Enzmann
Publikováno v:
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 51:731-739
The centralised procedure for marketing authorisation at the European Medicines Agency (EMEA) started more than 10 years ago, offering marketing authorisation for all member states of the European Union in a single procedure. Originally it was a pure
Autor:
C. K. Schneider, U. Kalinke
Publikováno v:
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 50:1213-1220
Der Einsatz monoklonaler Antikorper hat auf vielen klinischen Gebieten zu neuen therapeutischen Moglichkeiten gefuhrt. Er birgt aber auch Risiken, wie das akute Auftreten eines Zytokinsturms bei der Erstanwendung von TGN1412, einem Superagonisten geg
Autor:
C K, Schneider, M, Weise
Publikováno v:
Zeitschrift fur Rheumatologie. 74(8)
Biosimilars are currently a hot topic and there are many unsolved questions, misunderstandings and sometimes considerable uncertainty, especially among clinicians and patients. Regulatory agencies, such as the European Medicines Agency (EMA) issue gu
Publikováno v:
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 54(7)
Advanced therapy medicinal products (ATMP) are highly innovative and complex medicines. They comprise gene therapy medicinal products, somatic cell therapy medicinal products, and tissue-engineered products (TEP). With the European Regulation on ATMP
Publikováno v:
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 54(7)
Autor:
T, Montag-Lessing, M, Störmer, U, Schurig, J, Brachert, M, Bubenzer, U, Sicker, R, Beshir, I, Spreitzer, B, Löschner, C, Bache, B, Becker, C K, Schneider
Publikováno v:
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 53(1)
Today, sterility of parenteral drugs is practically guaranteed. Well-defined procedures in the pharmaceutical industry enable effective protection against contamination by bacteria and fungi. In contrast, problems regarding microbial safety of advanc
Autor:
M, Schüssler-Lenz, C K, Schneider
Publikováno v:
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 53(1)
For advanced therapies, the same basic principles for assessment apply as for any other biotechnological medicinal product. Nevertheless, the extent of data for quality, safety, and efficacy can be highly specific. Until recently, advanced therapies
Autor:
C K, Schneider, U, Kalinke
Publikováno v:
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 50(10)
The use of monoclonal antibodies has led to new therapeutic possibilities for many clinical conditions. However, their application also bears risks, as demonstrated by the acute occurrence of a cytokine storm following administration of TGN1412, an a
Autor:
C. K. Schneider, J. Löwer
Publikováno v:
Biologics in General Medicine ISBN: 9783540290179
Based on his observations from selective histological staining of bacteria, Paul Ehrlich in 1900 published his idea that certain compounds could be used as “magic bullets” to selectively target external pathogens or even tumours (Ehrlich 1900). W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7f6599cf05ac60c1cae1c9ea58efcd4b
https://doi.org/10.1007/978-3-540-29018-6_16
https://doi.org/10.1007/978-3-540-29018-6_16